AzTrials
AzTrials

Acute Coronary SyndromePhase 4FFR-SELECTNCT02000661

Routine Versus Selective Use of FFR to Guide PCI

A Phase 4 study testing Fractional Flow Reserve (FFR) in people with Acute Coronary Syndrome and Coronary Atherosclerosis, run by Cardiology Research UBC at 4 sites in Canada.

Terminated

Stopped early. The study ended before it was planned to and will not resume.

Official record
Search all trials

Trial summary

Fractional flow reserve (FFR) is a test that can be performed at the time of heart catheterization. It measures the change in pressure across a narrowing in the heart artery during high flow situation, and provides reliable information about the functional severity of the narrowing. Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
Fractional Flow Reserve (FFR)
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
261 participants
Where
4 sitesCanada
Study dates
Jan 2014to Feb 2017
Phase
Phase 4
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Subjects with stable coronary artery disease or recent acute coronary syndrome (ACS). Subjects who present with ST elevation myocardial infarction (STEMI) are allowed to be included after 5 days from initial presentation.
  • At least one obstructive coronary lesion is present with vessel reference diameter ≥2.5 mm and diameter stenosis ≥50% by visual estimate. Lesions must be technically suitable for the FFR procedure and angioplasty with stent placement.
  • Physician will classify all target lesions and need for FFR before randomization, and there is a plan to perform a non-emergent PCI.
  • Subject is ≥18 years old, with signed informed consent.

Who cannot join

  • Expected non-cardiac longevity < 2 years.
  • Planned treatment with CABG.
  • Planned treatment with medical therapy.
  • Left main disease > 50% diameter stenosis based on visual estimate.
  • Safety issues:
  • Unstable hemodynamics or serious arrhythmias during procedure;
Show all 24Show fewer
  • Ongoing ischemic chest pain;
  • High grade AV block (unless pacemaker);
  • Allergic to adenosine.
  • When FFR is clearly not needed:
  • Target vessel with slow flow (< TIMI-3);
  • Single vessel disease with ≥90% stenosis;
  • Single vessel disease with ≥80% stenosis and documented ischemia on functional imaging test;
  • In acute coronary syndrome, ≥70 stenosis identified as culprit.
  • When FFR is clearly needed for all target lesions: as declared by the operator.
  • Technical difficulty:
  • Severe vessel tortuosity;
  • Severe coronary calcification;
  • Anticipate difficult wiring;
  • Aorto-ostial lesion (ok for IV adenosine is used as the hyperemic agent).
  • Interpretation difficulty:
  • Target vessel acting as a major collateral donor;
  • When RA pressure very high;
  • STEMI within past 5 days.

Trial locations and contacts

4 sites in 1 country.

Canada4 sites
  • Kelowna General Hospital

    Kelowna, British Columbia

  • St. Paul's Hospital

    Vancouver, British Columbia

  • Vancouver General Hospital

    Vancouver, British Columbia

  • Royal Jubilee Hospital

    Victoria, British Columbia

Other trials in Canada

About this study

Official title: A Randomized Comparative Effectiveness Study of Routine Versus Selective Use of Fractional Flow Reserve (FFR) to Guide Non-Emergent Percutaneous Coronary Intervention (PCI)

Fractional flow reserve (FFR) is a test that can be performed at the time of heart catheterization. It measures the change in pressure across a narrowing in the heart artery during high flow situation, and provides reliable information about the functional severity of the narrowing. FFR measurements accurately predict whether a stent is needed, and is considered an excellent test before placement of stents to treat narrowed heart arteries. However, FFR is not used in every case because of the extra time needed and the associated device costs. Cardiac Services BC (an agency of Provincial Health Services Authority) is sponsoring this study to find out if FFR should be used in most cases (routine), rather than the current selective approach.

Read the detailed description

Percutaneous coronary intervention (PCI) is an effective, less invasive mode of revascularization compared with coronary artery bypass grafting (CABG). In 2011, a total of 7,614 PCI procedures were performed in British Columbia (BC). While some procedures were done emergently for life-threatening indications (e.g. ST elevation myocardial infarction - STEMI or cardiogenic shock), most (6,169 cases in year 2011) were done at the discretion of the treating physicians, taking patient preference into account. A number of factors are usually considered before proceeding with PCI. These may include clinical presentation (stable angina versus acute coronary syndrome); severity of symptoms (asymptomatic or highly symptomatic); response to medical therapy; severity of ischemia based on non-invasive functional testing (mild, moderate, or severe); predicted risk (low, intermediate, or high); and findings on coronary angiography (lesion number, location, severity, and morphology, etc). However, interpretation of symptoms is subjective. Non-invasive tests for ischemia may not be reliable. In addition, coronary angiography uses 2 dimensional images to depict 3-dimensional structures, and there is well known limitations.

The concept of using fractional flow reserve (FFR) to predict the functional significance of coronary lesions was described > 20 years ago. In 1996, Pijls et al showed that measurements of FFR in the cardiac catheterization laboratory can accurately predict provoked ischemia upon non-invasive functional testing. The DEFER study (2007) showed that coronary lesions with non-ischemic FFR values can be treated with medical therapy with good clinical outcome at 5-year follow up. The FAME-1 study (2009) evaluated the strategy of PCI guided by angiography versus PCI guided by FFR measurements in multi-vessel disease. The primary end-point was the 1-year composite of death, myocardial infarction (MI), and any repeat revascularization. Fewer stents were used per patient for the FFR-guided group (2.7 versus 1.9 stents per patient), less contrast agent used (302 versus 272 ml), and lower in-lab equipment cost ($6,007 US versus $5,332 US), all significant with P<0.001. A total of 1,005 patients were randomized. At 1-year follow up, the composite end-point of death, MI and target vessel revascularization was 18.2% for the angiography-guided group versus 13.3% for the FFR-guided group (p < 0.02). At 2-year follow up, the incidence of death and MI was lower for the FFR-guided group (12.7% versus 8.4%, p<0.03), and the incidence of MI in the FFR-guided and PCI deferred population was very low at 0.2%.

Since the publication of the FAME-1 study, the use of pressure wires to measure FFR increased from ~400 cases per year to ~1,000 cases per year in BC. However, in comparison with an annual non-emergent PCI volume of >6,000 cases per year, the use of FFR appears highly selective (1,058 out of 6,169, 17%, based on year 2011 statistics). In a series of 442 consecutive FFR cases done at the Vancouver General and St. Paul's Hospitals (year 2011 to 2012), the use of FFR identified non-ischemic lesions in 52%, and this resulted in a change in management decision in 68%. In addition, provincial data showed significant variation in the use of FFR among the 5 PCI capable hospitals in BC (from <5% to ~30%). Based on the recent European Society of Cardiology guidelines, the use of FFR to guide revascularization has a class 1a indication in multi-vessel disease, while the US guidelines (American College of Cardiology, ACC) has a class 2a recommendation for the use of FFR in evaluating coronary lesions of intermediate severity. It is possible that a highly selective approach to the use of FFR may lead to underuse, which in turn may lead to overuse of PCI, with increased cost, and adverse clinical outcome.

We hypothesize that the routine use of FFR may improve clinical outcome, decrease the number of PCI, and decrease direct cost in the cardiac catheterization laboratory. We propose a randomized study to compare 2 approaches of using FFR to guide PCI: (1) routine use - the experimental arm; and (2) selective use - the current standard.

Being tested
Fractional Flow Reserve (FFR)
Keywords
Fractional Flow Reserve (FFR), FFR guided coronary interventions, Percutaneous Coronary Intervention
Medical subject headings
Acute Coronary Syndrome, Coronary Artery Disease, Angina, Unstable

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Fractional Flow Reserve (FFR)Device

    Also called FFR Wire (PressureWire™ by St. Jude Medical)

    Fractional Flow Reserve (FFR) performed per guidelines to guide PCI

Study groups in NCT02000661
Study groupRoleWhat they receive
Routine use of FFRExperimentalFractional Flow Reserve (FFR) used in most cases to guide PCI
Receives: Device: Fractional Flow Reserve (FFR)
Selective use of FFRActive comparatorFractional Flow Reserve (FFR) used at investigator discretion (Current practice)
Receives: Device: Fractional Flow Reserve (FFR)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Composite of all cause mortality, repeat hospitalization for MI or repeat revascularization (PCI or coronary artery bypass grafting - CABG)

    Measured: 1 Year

Secondary outcomes (4)
  1. All cause mortality

    Measured: 1 Year

  2. Repeat hospitalization for MI

    Measured: 1 Year

  3. Rate of repeat revascularization (PCI or CABG)

    Measured: 1 Year

  4. Time of procedure, contrast amount, and radiation dose

    Measured: Post-procedure

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted4 Dec 2013 (estimated)
  2. Study startJan 2014
  3. Primary completionFeb 2017
  4. Study completionFeb 2017

Why it stopped: Stopped early by DSMB due to slow enrollment - obtained data to be analyzed

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
261 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02000661
Sponsor's protocol ID
H13-02709
Acronym
FFR-SELECT
Status last verified
Feb 2019
First submitted
27 Nov 2013
Last updated
26 Feb 2019
Results posted
No
Data monitoring committee
No

Questions about this trial

What is this clinical trial studying?

A Phase 4 study testing Fractional Flow Reserve (FFR) in people with Acute Coronary Syndrome and Coronary Atherosclerosis, run by Cardiology Research UBC at 4 sites in Canada.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 24 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: stopped early, as of the sponsor's last update on 26 Feb 2019. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 4 sites in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study was stopped early (reason given: Stopped early by DSMB due to slow enrollment - obtained data to be analyzed). Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Composite of all cause mortality, repeat hospitalization for MI or repeat revascularization (PCI or coronary artery bypass grafting - CABG) (time frame: 1 Year). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Feb 2019.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in